Endocrinology, Diabetes & Metabolism Doctors in Monterey, CA Accepting Medicare

4 Endocrinology, Diabetes & Metabolism doctors found. Showing 1 - 4

Resmi Premji, Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2 Upper Ragsdale Dr Bldg A, Monterey, CA 93940 Phone: 831-333-3040    Fax: 831-886-3639

Dr. Leonard Rene Sanders, M.D. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2 Upper Ragsdale Dr Bldg A, Monterey, CA 93940 Phone: 831-333-3040    Fax: 831-886-3639

Somayeh D. Azimi, D.O. Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 2 Upper Ragsdale Dr Bldg A, Monterey, CA 93940 Phone: 480-373-2370

Dr. James W Chu, MD Internal Medicine - Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 2 Upper Ragsdale Dr, Suite B-200, Monterey, CA 93940 Phone: 831-375-6334    Fax: 831-375-6331

News Archive

New insight: p53 protein controls molecular crossroads in glucose metabolic pathway

The gene for the protein p53 is the most frequently mutated in human cancer. It encodes a tumor suppressor, and traditionally researchers have assumed that it acts primarily as a regulator of how genes are made into proteins.

European project to define key stages of human ageing

Aston University in Birmingham, UK, is one of 27 partners involved in a EUR 12m project that is set to identify and establish biomarkers which recognise the key stages of human ageing.

Type of cellular stress called osmotic stress is critical to cell growth and the body's immune response against infection

Researchers at the University of California, San Diego (UCSD) School of Medicine have determined that a particular type of cellular stress called osmotic stress is of critical importance to cell growth and the body's immune response against infection.

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

Read more Medical News

› Verified 2 days ago